Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Trial of Setmelanotide in Acquired Hypothalamic Obesity
A Trial of Setmelanotide in Acquired Hypothalamic Obesity

NCT05774756

Active Not RecruitingPhase 3

Sponsor: Rhythm Pharmaceuticals, Inc.

Conditions: Hypothalamic Obesity

Interventions: Setmelanotide, Placebo

Countries: United States, Canada, Germany, Japan, Netherlands, United Kingdom

The goal of this trial is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with acquired Hypothalamic Obesity (HO). To determine how well setmelanotide works and how safe it is, patients with HO will take a daily injection of either setmelanotide or placebo and complete trial assessments for 52 weeks on a therapeutic regimen. A separate sub-study in patients with congenital HO is detailed under NCT06760546.

Eligibility overview

Sex: ALL

Age: 4 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Key Inclusion Criteria:

1. Documented evidence of acquired hypothalamic obesity (HO)
2. Age 4 years and older
3. Weight gain associated with the hypothalamic injury and a BMI of ≥30 kg/m2 for patients ≥18 years of age or BMI ≥95th percentile for age and sex for patients 4 to \<18 years of age
4. Agree to use a highly effective form of contraception throughout the study and for 90 days after the study

Key Exclusion Criteria:

1. Diagnosis of Prader-Willi syndrome (PWS) or Rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, neuroendocrine tumor syndrome (ROHHADNET)
2. Weight loss \>2% in the previous 3 months for patients aged ≥18 years or \>2% reduction in BMI for patients aged 4 to \<18 years
3. Bariatric surgery or procedure within last 2 years
4. Diagnosis of severe psychiatric disorders; any suicidal ideation, attempt or behavior
5. Current, clinically significant pulmonary, cardiac, metabolic, or oncologic disease
6. Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion)
7. History or close family history of skin cancer or melanoma
8. Participation in any clinical trial with an investigational drug/device within 3 months prior to the first trial dose
9. Previously enrolled in a clinical trial involving setmelanotide or any previous exposure to setmelanotide
10. Inability to comply with once daily (QD) injection regimen
11. If female, pregnant and/or breastfeeding
12. Patients with obesity attributable to other genetic or syndromic conditions (eg, PPL \[POMC, PCSK1, LEPR, collectively\], BBS) prior to the hypothalamic injury.
13. If receiving hormone replacement therapy, dose has remained stable for at least 2 months before Screening

Other protocol defined Inclusion/Exclusion criteria may apply.
Locations (28)
  • Birmingham, Alabama, United States
  • San Diego, California, United States
  • Aurora, Colorado, United States
  • Gainesville, Florida, United States
  • Chicago, Illinois, United States
  • Iowa City, Iowa, United States
  • Boston, Massachusetts, United States
  • Boston, Massachusetts, United States
  • Saint Paul, Minnesota, United States
  • New York, New York, United States
  • New York, New York, United States
  • Columbus, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Philadelphia, Pennsylvania, United States
  • Nashville, Tennessee, United States
  • Seattle, Washington, United States
  • Toronto, Ontario, Canada
  • Hamburg, Germany
  • München, Germany
  • Oldenburg, Germany
  • Ulm, Germany
  • Nagoya, Aichi-ken, Japan
  • Azumino, Nagano, Japan
  • Minato, Tokyo, Japan
  • Utrecht, Netherlands
  • Birmingham, United Kingdom
  • Hull, United Kingdom
  • London, United Kingdom